Brought to you by 
Series F brings $200mm to Tempus Labs
17 Jun 2019
Executive Summary
AI and precision medicine firm Tempus Labs Inc. raised $200mm through its Series F round from investors including Baillie Gifford, Franklin Templeton, NEA, Novo Holdings, Revolution Growth, and funds managed by T. Rowe Price. Novo Holdings takes a board seat.
Deal Industry
- Digital Health
- In Vitro Diagnostics
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
- Services
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com